{
    "Clinical Trial ID": "NCT00322374",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Ixabepilone 25 mg^m2 + Epirubicin 75 mg^m2",
        "  Participants received 25 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days.",
        "INTERVENTION 2: ",
        "  Ixabepilone 30 mg^m2 + Epirubicin 75 mg^m2",
        "  Participants received 30 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Women 18 years",
        "  Histologically or cytologically confirmed diagnosis of metastatic breast cancer",
        "  Measurable or nonmeasurable disease defined by Response Evaluation Criteria In Solid Tumors (RECIST)",
        "Exclusion Criteria:",
        "  Number of prior chemotherapy lines of treatment in the metastatic setting 2"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Participants With a Dose Limiting Toxicity (DLT)",
        "  DLT: any of the following considered related to ixabepilone, epirubicin or combination occurring in Cycle 1: Absolute neutrophil count <500 cells/mm^3 for 7 consecutive days or febrile neutropenia of any duration;Grade(Gr)4 thrombocytopenia <25,000 cells/mm^3 or Gr3 w/bleeding requiring platelet transfusion;Any other drug-related Gr3/4 non-hematologic toxicity except Gr3 injection site reaction, fatigue, transient arthralgia/myalgia;Delayed recovery to Gr  1 or baseline (except for alopecia) from toxicity related to treatment w/ ixabepilone + epirubicin delaying initiation of next cycle 3 wks",
        "  Time frame: From Baseline to the end of Cycle 1 (Day 21)",
        "Results 1: ",
        "  Arm/Group Title: Ixabepilone 25 mg^m2 + Epirubicin 75 mg^m2",
        "  Arm/Group Description: Participants received 25 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days.",
        "  Overall Number of Participants Analyzed: 6",
        "  Measure Type: Number",
        "  Unit of Measure: Participants  Participants with DLT:Grade 4 (severe) neutropenia: 1",
        "  Total Participants with DLT: 1",
        "  Participants without DLT: 5",
        "Results 2: ",
        "  Arm/Group Title: Ixabepilone 30 mg^m2 + Epirubicin 75 mg^m2",
        "  Arm/Group Description: Participants received 30 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days.",
        "  Overall Number of Participants Analyzed: 6",
        "  Measure Type: Number",
        "  Unit of Measure: Participants  Participants with DLT:Grade 4 (severe) neutropenia: 1",
        "  Total Participants with DLT: 1",
        "  Participants without DLT: 5"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 2/6 (33.33%)",
        "  ANAEMIA 0/6 (0.00%)",
        "  NEUTROPENIA 0/6 (0.00%)",
        "  FEBRILE NEUTROPENIA 0/6 (0.00%)",
        "  FEBRILE BONE MARROW APLASIA 0/6 (0.00%)",
        "  NAUSEA 0/6 (0.00%)",
        "  VOMITING 1/6 (16.67%)",
        "  PYREXIA 0/6 (0.00%)",
        "  HYPERSENSITIVITY 1/6 (16.67%)",
        "  PLATELET COUNT DECREASED 0/6 (0.00%)",
        "  BACK PAIN 0/6 (0.00%)",
        "  SYNCOPE 0/6 (0.00%)",
        "  CEREBROVASCULAR ACCIDENT 0/6 (0.00%)",
        "Adverse Events 2:",
        "  Total: 8/30 (26.67%)",
        "  ANAEMIA 1/30 (3.33%)",
        "  NEUTROPENIA 0/30 (0.00%)",
        "  FEBRILE NEUTROPENIA 1/30 (3.33%)",
        "  FEBRILE BONE MARROW APLASIA 2/30 (6.67%)",
        "  NAUSEA 2/30 (6.67%)",
        "  VOMITING 0/30 (0.00%)",
        "  PYREXIA 2/30 (6.67%)",
        "  HYPERSENSITIVITY 0/30 (0.00%)",
        "  PLATELET COUNT DECREASED 0/30 (0.00%)",
        "  BACK PAIN 1/30 (3.33%)",
        "  SYNCOPE 0/30 (0.00%)",
        "  CEREBROVASCULAR ACCIDENT 1/30 (3.33%)"
    ]
}